TriangleNCT01457417 · OUTCOME
Overall Survival (OS) in Patients With Relapsed or Refractory NSCLC
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Time from the date of signed informed consent to the date of death from any cause
What was measured
For Part B only. OS was defined as the time from the date of signed informed consent to the date of death from any cause. For patients who were still alive as of the data cut-off date, OS time was censored on the date of the patient's last contact (last contact for patients in post-discontinuation was the last date of contact in long-term follow-up eCRF).
Analysis population: For patients who are still alive as of the data cut-off date, OS time will be censored on the date of the patient's last contact (last contact for patients in post-discontinuation = last Date of Contact in Long Term Follow-up eCRF).
Groups in this outcome
300 mg DKN-01 Part B (Q2W)
Dose Confirmation: Once the MTD had been established or the highest planned dose level completed, 300 mg of DKN-01 was administered as IV on days 1 and 15 of every 28 day cycle.
| Group | Source count |
|---|---|
| 300 mg DKN-01 Part B (Q2W) | 19 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| 300 mg DKN-01 Part B (Q2W) | 6.6 | Not reported | 4.1 | 10.1 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 4.1
- upper Limit
- 10.1
- value
- 6.6
- denoms
- counts
- group Id
- OG000
- value
- 19
- units
- Participants
- description
- For Part B only. OS was defined as the time from the date of signed informed consent to the date of death from any cause. For patients who were still alive as of the data cut-off date, OS time was censored on the date of the patient's last contact (last contact for patients in post-discontinuation was the last date of contact in long-term follow-up eCRF).
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Dose Confirmation: Once the MTD had been established or the highest planned dose level completed, 300 mg of DKN-01 was administered as IV on days 1 and 15 of every 28 day cycle.
- id
- OG000
- title
- 300 mg DKN-01 Part B (Q2W)
- param Type
- MEDIAN
- population Description
- For patients who are still alive as of the data cut-off date, OS time will be censored on the date of the patient's last contact (last contact for patients in post-discontinuation = last Date of Contact in Long Term Follow-up eCRF).
- reporting Status
- POSTED
- time Frame
- Time from the date of signed informed consent to the date of death from any cause
- title
- Overall Survival (OS) in Patients With Relapsed or Refractory NSCLC
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice